Related Experiment Video
Updated: Nov 12, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal
Christos Papageorgiou1, Flora Zagouri1, Konstantinos Tampakis1
1Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Insights
Cyclin-dependent kinase (CDK) 4/6 inhibitors combined with hormonal therapy increase vascular inflammation and blood pressure in metastatic breast cancer patients. Both CDK 4/6 inhibitors and everolimus treatments promote left ventricle remodeling.
Area of Science:
- Cardiovascular Medicine
- Oncology
- Radiology
Background:
- Chemotherapy for breast cancer can cause vascular dysfunction and cardiovascular risks.
- Metastatic breast cancer patients face significant cardiovascular challenges during treatment.
Purpose of the Study:
- To assess cardiovascular burden and vascular inflammation in metastatic breast cancer patients.
- To compare the effects of CDK 4/6 inhibitors versus everolimus on cardiovascular parameters.
Main Methods:
- Echocardiography for relative wall thickness (RWT) and left ventricle mass (LVM).
- 24-h ambulatory blood pressure monitoring.
- 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG-PET/CT) for aortic uptake (TBR).
Main Results:
- CDK 4/6 inhibitors significantly increased 24-h systolic and diastolic blood pressure and aortic inflammation (TBR).
- Everolimus showed stable blood pressure and aortic TBR compared to CDK 4/6 inhibitors.
- Both regimens led to detrimental effects on RWT and LVM, indicating left ventricle remodeling.
Conclusions:
- CDK 4/6 inhibitors plus hormonal treatment elevate vascular inflammation and blood pressure more than everolimus plus hormonal treatment.
- Both therapeutic strategies contribute to left ventricle remodeling in metastatic breast cancer patients.
Abstract:
Background: Chemotherapy regimens for breast cancer treatment can promote vascular dysfunction and lead to high cardiovascular risk. Purpose: To investigate the cardiovascular burden and vascular inflammation in metastatic breast cancer patients receiving CDK 4/6 inhibitors or everolimus in addition to standard hormonal treatment. Methods: 22 consecutive female patients with metastatic breast cancer were enrolled. Relative wall thickness (RWT) and left ventricle mass (LVM) measurements by transthoracic echocardiography were obtained followed by 24-h ambulatory blood pressure monitoring, and 18F-fluorodeoxyglucose positron-emission tomography/computed tomography imaging. Uptake of the radiotracer in the aortic wall was estimated as tissue-to-background ratio (TBR). Each patient was assessed for the aforementioned parameters before the initiation and after 6 months of treatment. Results: At follow up, patients assigned to CDK 4/6 treatment demonstrated increased 24-h systolic blood pressure (SBP) (p = 0.004), daytime SBP (p = 0.004) and night time SBP (p = 0.012) (Group effect). The 24-h mean arterial pressure measurements were also higher in CDK 4/6 population, in comparison to everolimus that displayed firm values (Group effect- p = 0.035, Interaction effect-p = 0.023). Additionally, 24 h diastolic blood pressure recordings in CDK 4/6 therapy were higher opposed to everolimus that remained consistent (Interaction effect- p = 0.010). In CDK 4/6 group, TBR aorta also increased significantly, whereas TBR values in everolimus remained stable (Interaction effect-p = 0.049). Both therapeutic regimens displayed statistically significant damaging effect to RWT and LVM. Conclusion: CDK 4/6 inhibitors and hormonal treatment can lead to increased vascular inflammation, and higher blood pressure compared to the combination of everolimus and hormonal treatment. Moreover, both treatment strategies promoted left ventricle remodeling.
More Related Videos
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
05:02Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
Published on: February 4, 2021
Related Concept Videos
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...